JP7724239B2 - アデノシンａ２ａ受容体のアンタゴニスト - Google Patents

アデノシンａ２ａ受容体のアンタゴニスト

Info

Publication number
JP7724239B2
JP7724239B2 JP2022567895A JP2022567895A JP7724239B2 JP 7724239 B2 JP7724239 B2 JP 7724239B2 JP 2022567895 A JP2022567895 A JP 2022567895A JP 2022567895 A JP2022567895 A JP 2022567895A JP 7724239 B2 JP7724239 B2 JP 7724239B2
Authority
JP
Japan
Prior art keywords
methyl
pyrazolo
pyridyl
chloro
cyanophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525762A5 (enExample
JP2023525762A (ja
Inventor
マッカーシー，クライヴ
モールトン，ベンジャミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AdoRx Therapeutics Ltd
Original Assignee
AdoRx Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006823.5A external-priority patent/GB202006823D0/en
Priority claimed from GBGB2019922.0A external-priority patent/GB202019922D0/en
Application filed by AdoRx Therapeutics Ltd filed Critical AdoRx Therapeutics Ltd
Publication of JP2023525762A publication Critical patent/JP2023525762A/ja
Publication of JP2023525762A5 publication Critical patent/JP2023525762A5/ja
Priority to JP2025130117A priority Critical patent/JP2025183201A/ja
Application granted granted Critical
Publication of JP7724239B2 publication Critical patent/JP7724239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022567895A 2020-05-07 2021-05-06 アデノシンａ２ａ受容体のアンタゴニスト Active JP7724239B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025130117A JP2025183201A (ja) 2020-05-07 2025-08-04 アデノシンａ２ａ受容体のアンタゴニスト

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2006823.5A GB202006823D0 (en) 2020-05-07 2020-05-07 Antagonist compounds
GB2006823.5 2020-05-07
GBGB2019922.0A GB202019922D0 (en) 2020-12-16 2020-12-16 Antagonist compounds
GB2019922.0 2020-12-16
PCT/GB2021/051106 WO2021224636A1 (en) 2020-05-07 2021-05-06 Antagonists of the adenosine a2a receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025130117A Division JP2025183201A (ja) 2020-05-07 2025-08-04 アデノシンａ２ａ受容体のアンタゴニスト

Publications (3)

Publication Number Publication Date
JP2023525762A JP2023525762A (ja) 2023-06-19
JP2023525762A5 JP2023525762A5 (enExample) 2024-05-17
JP7724239B2 true JP7724239B2 (ja) 2025-08-15

Family

ID=75977772

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022567895A Active JP7724239B2 (ja) 2020-05-07 2021-05-06 アデノシンａ２ａ受容体のアンタゴニスト
JP2025130117A Pending JP2025183201A (ja) 2020-05-07 2025-08-04 アデノシンａ２ａ受容体のアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025130117A Pending JP2025183201A (ja) 2020-05-07 2025-08-04 アデノシンａ２ａ受容体のアンタゴニスト

Country Status (17)

Country Link
US (1) US12617796B2 (enExample)
EP (1) EP4146654A1 (enExample)
JP (2) JP7724239B2 (enExample)
KR (1) KR20230035236A (enExample)
CN (2) CN115996929B (enExample)
AU (1) AU2021266433A1 (enExample)
BR (1) BR112022022437A2 (enExample)
CA (1) CA3181354A1 (enExample)
CL (1) CL2022003055A1 (enExample)
CO (1) CO2022017618A2 (enExample)
EC (1) ECSP22091613A (enExample)
GB (1) GB2609879B (enExample)
IL (2) IL297963A (enExample)
MX (1) MX2022013946A (enExample)
PE (1) PE20230769A1 (enExample)
PH (1) PH12022552987A1 (enExample)
WO (1) WO2021224636A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114157A2 (en) * 2021-12-17 2023-06-22 Merck Sharp & Dohme Llc Pyrazolopyrimidine derivatives and methods of use thereof for the treatment of herpesviruses
CN116283994B (zh) * 2021-12-20 2025-01-07 艾立康药业股份有限公司 作为mat2a抑制剂的杂环化合物
EP4467545A4 (en) * 2022-01-18 2026-01-21 Jiangsu Yayo Biotechnology Co Ltd NEW TYPE OF COMPOUND PYRAZOLOPYRIMIDINE AND ASSOCIATED COMPOSITION, PREPARATION PROCESS AND USE
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
WO2025054448A1 (en) * 2023-09-08 2025-03-13 Satellos Bioscience Inc. Ap2 associated kinase 1 inhibitors and uses thereof
TW202535406A (zh) 2023-10-30 2025-09-16 美商壯生和壯生企業創新公司 用於治療肺癌之a2a受體拮抗劑
WO2025123253A1 (en) 2023-12-13 2025-06-19 Johnson & Johnson Enterprise Innovation Inc. Pharmaceutical compositions of an a2a receptor antagonist
WO2025123251A1 (en) 2023-12-13 2025-06-19 Johnson & Johnson Enterprise Innovation Inc. Crystalline forms of a2a receptor antagonist, preparation methods, and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025202955A1 (en) 2024-03-28 2025-10-02 Pi Industries Ltd. Fused bicyclic compounds and their use as pest control agents
CN120093763A (zh) * 2025-03-25 2025-06-06 上海天龙生物科技有限公司 治疗前列腺疾病和腺体类散结节的药物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091256A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
JP2011513334A (ja) 2008-02-29 2011-04-28 ワイス・エルエルシー ピラゾロ［１，５−ａ］ピリミジンの架橋二環式複素環式またはスピロ二環式複素環式誘導体、その調製方法および使用
JP2017502069A (ja) 2014-01-09 2017-01-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910907A (en) 1973-07-09 1975-10-07 Icn Pharmaceuticals Pyrazolo(1,5-a)-1,3,5-triazines
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
ATE257703T1 (de) 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2347909A1 (en) 1998-12-18 2000-06-22 Joseph B. Santella, Iii N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ATE302005T1 (de) 1998-12-18 2005-09-15 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
EP1156807A4 (en) 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
AU2057200A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
WO2001010865A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001098270A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1363881A2 (en) 2000-06-21 2003-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
ATE404568T1 (de) 2001-03-14 2008-08-15 Gruenenthal Gmbh Substituierte thiazolopyrimidine als analgetika
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
KR20030083016A (ko) 2001-03-28 2003-10-23 브리스톨-마이어스스퀴브컴파니 신규 타이로신 카이나제 억제제
EP1402900A1 (en) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
EP1441732A2 (en) 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
JP4638355B2 (ja) 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
PL380764A1 (pl) 2003-12-31 2007-03-19 Schering-Plough Ltd. Kontrolowanie pasożytów u zwierząt za pomocą stosowania imidazo [1,2-b] pirydazynowych pochodnych
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
JP2008542323A (ja) * 2005-06-01 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２−オキソ−１−ピロリジン誘導体、その製造方法及びその使用
BRPI0812504B8 (pt) * 2007-06-21 2021-05-25 Cara Therapeutics Inc composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
WO2009027733A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009060197A1 (en) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
EP2103614A1 (en) 2008-03-18 2009-09-23 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402343A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole-fused bicyclic compounds
EP2402345A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402337A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2012100342A1 (en) * 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
WO2012113774A1 (en) 2011-02-24 2012-08-30 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
UA114490C2 (uk) 2011-10-06 2017-06-26 Байєр Інтеллектуал Проперті Гмбх Гетероциклілпіри(mі)динілпіразоли як фунгіциди
AR088082A1 (es) 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
CN104418821A (zh) 2013-08-22 2015-03-18 四川大学华西医院 2,4位取代的5-(3,4,5-三甲氧基苯基)噻唑衍生物及其制备方法和用途
CN107257796A (zh) * 2014-12-02 2017-10-17 拜耳医药股份有限公司 取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
EP3442980B1 (en) * 2016-04-15 2021-06-09 Cancer Research Technology Limited Heterocyclic compounds as ret kinase inhibitors
CN110072865B (zh) * 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
US20240226098A1 (en) 2020-02-28 2024-07-11 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20230167093A1 (en) 2020-04-08 2023-06-01 Remix Therapeutics Inc. Compounds and methods for modulating splicing
KR20230004575A (ko) 2020-04-08 2023-01-06 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
TWI782504B (zh) 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物
GB202011996D0 (en) 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
GB202019622D0 (en) 2020-12-11 2021-01-27 Adorx Therapeutics Ltd Antagonist compounds
WO2022130290A1 (en) 2020-12-16 2022-06-23 New Frontier Labs, Llc Dicarboxylic acid esters for the treatment of diseases and conditions associated with phospholipase d toxin
US11845760B2 (en) 2020-12-16 2023-12-19 Amgen Inc. PRMT5 inhibitors
MX2023006728A (es) 2020-12-16 2023-06-19 New Frontier Labs Llc Esteres de acido dicarboxilico para inducir un efecto analgesico.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091256A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
JP2011513334A (ja) 2008-02-29 2011-04-28 ワイス・エルエルシー ピラゾロ［１，５−ａ］ピリミジンの架橋二環式複素環式またはスピロ二環式複素環式誘導体、その調製方法および使用
JP2017502069A (ja) 2014-01-09 2017-01-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dennis R. Compton, et al.，"Pyrazolo[1,5-a]pyrimidines: Estrogen Receptor Ligands Possessing Estrogen Receptor β Antagonist Activity"，J. Med. Chem，2004年，Vol.47，pp.5872-5893
REGISTRY(STN)[Online]，2015年，CAS登録番号：1782806-38-5, 1496301-75-7等

Also Published As

Publication number Publication date
AU2021266433A1 (en) 2022-12-15
CN115996929A (zh) 2023-04-21
CN115996929B (zh) 2026-01-13
CL2022003055A1 (es) 2023-07-07
US12617796B2 (en) 2026-05-05
CA3181354A1 (en) 2021-11-11
US20230203041A1 (en) 2023-06-29
MX2022013946A (es) 2023-02-01
KR20230035236A (ko) 2023-03-13
IL324071A (en) 2025-12-01
WO2021224636A1 (en) 2021-11-11
BR112022022437A2 (pt) 2023-01-03
IL297963A (en) 2023-01-01
JP2023525762A (ja) 2023-06-19
JP2025183201A (ja) 2025-12-16
CO2022017618A2 (es) 2023-02-16
PE20230769A1 (es) 2023-05-09
GB202217519D0 (en) 2023-01-04
PH12022552987A1 (en) 2024-02-26
GB2609879B (en) 2023-08-16
GB2609879A (en) 2023-02-15
EP4146654A1 (en) 2023-03-15
ECSP22091613A (es) 2023-03-31
CN122010947A (zh) 2026-05-12

Similar Documents

Publication Publication Date Title
US12617796B2 (en) Antagonists of the adenosine A2a receptor
JP7805350B2 (ja) アンタゴニスト化合物
AU2021397402A1 (en) Antagonists of the adenosine a2a receptor
WO2022090711A1 (en) Compounds as cd73 inhibitors
JP2024522201A (ja) 置換された１，２－ジアミノヘテロサイクリック化合物誘導体の製造およびその薬剤としての用途
HK40130881A (en) Antagonist compounds
US20250243194A1 (en) Antagonist of adenosine receptors
WO2023233130A1 (en) Cd73 inhibitor compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250321

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250804

R150 Certificate of patent or registration of utility model

Ref document number: 7724239

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150